Cardiovascular

If approved, Evkeeza would be the first treatment to help children as young as 5 years old control high LDL cholesterol caused by homozygous familial hypercholesterolemia. The FDA target action date is March 30, 2023.

If approved, Xphozah will be the first phosphate absorption inhibitor for adults with chronic kidney disease who are on dialysis. An FDA decision is expected within 30 days.

Furoscix can be administered at home with the use of the On-Body Infusor, which delivers furosemide over five hours. It will be launched in the first quarter of 2023.

Results indicated the trial is unlikely to meet its primary endpoint, the change from baseline in the six-minute walk test at 24 weeks.

A novel therapy in early development aims to permanently turn off the PCSK9 gene in the liver and lower cholesterol with a one-time treatment. It is being developed for a genetic form of high cholesterol.

Now called Camzyos, the therapy is first-in-class and treats the underlying cause of the disease. It is expected to be available next week.

The recall of Accuretic and generics distributed by Greenstone is a result of the presence of a cancer-causing agent.

But there is no significant difference in rate of hospitalization for major bleeding when Eliquis is compared with Xarelto or warfarin.

Researchers suggest that adjusting the prescribing patterns of about 8% of physicians could result in substantial savings.

The study found that nearly half of Americans diagnosed with high blood pressure do not have it sufficiently controlled.

Across all payers, the use of generic statins has resulted in a savings of $11.9 billion annually.

Besremi is the first interferon approved to treat a disease that causes the overproduction of red blood cells.

If approved, Jardiance would be the first treatment for adults across the full spectrum of heart failure regardless of ejection fraction.

Treating and managing patients with paroxysmal nocturnal hemoglobinuria is expensive and requires constant surveillance by the provider and health plan.

Investigators found only small differences in the change in LDL-C levels in the incentive groups versus the control group

Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.

Repatha is now available for children 10 and older to lower low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia.

Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure.

The full results from the Emperor-Preserved trial show Jardiance reduces the risk of hospital and death from heart failure.

Preliminary research shows Anplag could be repurposed as a heart failure treatment at a lower cost.

The findings were similar in people with or without diabetes.

Competition among branded products did not substantially curb annual spending increases.

Angiotensin receptor blockers may be less likely to cause side effects than ACE inhibitors.

Most of the suspected cases of myocarditis developed after the second dose of the vaccine and were among younger males.

This research sought to understand the relationship of prior medication exposure, existing health conditions, and COVID-19 outcomes using data from the American Heart Association’s COVID-19 Cardiovascular Disease Registry.

New data show efficacy in all forms of heart failure regardless of ejection fraction.

Adults taking medications that cross the blood-brain barrier had better memory recall.

Chances of left ventricular ejection fraction almost disappeared when patient took the ACE-inhibitor lisinopril during treatment with trastuzumab/anthracycline, according to research presented at ASCO.

The AstraZeneca drug is the first SGLT2 inhibitor approved for chronic kidney disease regardless of whether the patient has diabetes.

Application was submitted for both the 81 and 325 mg doses of the liquid-filled capsule formulation of aspirin.